dbv technologies

WELCOME

HARNESSING THE IMMUNE PROPERTIES OF THE SKIN

Given its central role in immune modulation, the skin is a critical target for therapeutic intervention in food allergy and other immunologic disorders.1 Epicutaneous immunotherapy (EPIT) is a noninvasive, innovative approach that aims to re-train the immune system over time.1-3

MECHANISM OF ACTION (MOA)

UTILIZING THE IMMUNE-REGULATING CAPABILITIES OF THE SKIN TO RE-TRAIN THE IMMUNE SYSTEM, USING FOOD ALLERGY AS AN EXAMPLE2,4,5

EPIT uses the tolerogenic immune properties of the skin to induce desensitization while limiting systemic allergen exposure.*

Treg, regulatory T cell.

*Based on animal model data.

WHY PEANUT?

Our Lead Clinical Trial Program Is investigating a patch-based technology for the treatment of Peanut Allergy

The annual incidence of peanut allergy has increased over time.8

Reactions can be unpredictable and severe, including the potential for anaphylaxis.9,10

Peanut allergy exerts a substantial burden that often lasts a lifetime.11,12

CLINICAL TRIALS

A Robust Clinical Development Program

In our lead program for peanut allergy17:

>1.1

MILLION

patches applied

~1600

children aged 1 to 7 years treated

In toddlers (1-3 years)18

ONGOING

COMFORT toddlers

Supplemental Safety

~480 patients

6-month phase 3 DBPC + 18-month OLE

In children (4-7 years)19,20

COMPLETED

VITESSE

Efficacy & Safety

654 patients

12-month phase 3 DBPC

In children (4-7 years)17,20

ONGOING

VITESSE Open-Label Extension

Open-Label Extension

Efficacy & Safety

507 patients

24-month OLE (up to 36 months total follow-up)

In toddlers (1-3 years)21

COMPLETED

epitope

Efficacy & Safety

362 patients

12-month phase 3 DBPC

In toddlers (1-3 years)22

COMPLETED

Epopex

Efficacy & Safety

266 patients

24-month OLE (36 months total follow-up)

In infants (6-12 months)17

ONGOING

THRIVE

Efficacy & Safety

~250 patients

48-month phase 2 open-label

DBPC, double-blind, placebo-controlled; OLE, open-label extension.

PIPELINE

Our Clinical Program Spans Food Allergy and Autoimmune/Inflammatory Disorders17

DEVELOPMENT STAGE

Program & Indication

Discovery
Pre-Clinical
Phase 1
Phase 2
Phase 3

Food Allergy

VIASKIN Peanut Patch

(DBV712)
Peanut Allergy

Ages 4-7 years

Ages 1-3 years

Ages 6-12 months*

VIASKIN Milk Patch

(DBV135)
Cow's Milk Allergy

Ages 2-17 years

Autoimmune & Inflammatory Disorders

Celiac Disease

Multiple Programs

*Study assessing the achievement of ad-lib dietary peanut consumption following a minimum of 3 years of treatment in patients enrolled at 6 through 12 months of age. Ad-lib consumption will be defined as the consumption amount and frequency that meets the treatment goals of the family or suggests that permanent tolerance has been achieved.17,23

dbv technologies

Epicutaneous immunotherapy and VIASKIN® Peanut Patch are under clinical investigation and have not yet been approved by any health or regulatory authority.

DBV is a global, clinical-stage biopharmaceutical company committed to transforming the lives of children and families living with the daily challenges of food allergy.

THANK YOU

QR code linking to dbv-technologies.com

Scan the QR code or visit
dbv-technologies.com
to find out more.

Epicutaneous immunotherapy and VIASKIN® Peanut Patch are under clinical investigation and have not yet been approved by any health or regulatory authority.

References: 1. Hervé PL et al. Front Allergy. 2023;4:1290003. 2. Ravindran M et al. Allergy. 2025;80(1):63-76 3. Dioszeghy V et al. J Immunol. 2011;186(10):5629-5637. 4. Hund SK et al. Front Immunol. 2025;16:1572283 5. Hwang DW et al. Immunother Adv. 2022;2:1-7. 6. Fleischer DM et al. Allergy Asthma Proc. 2020;41(5):326-335. 7. Mondoulet L et al. J Allergy Clin Immunol. 2015;135(6):1546-1557. doi:10.1016/j.jaci.2014.11.028 8. Mahr TA et al. J Allergy Clin Immunol Pract. 2021;9(4):1683-1694.e5. 9. Muraro A et al. Clin Transl Allergy. 2021;11(8)e12064. 10. Cherkaoui SY et al. Clin Transl Allergy. 2015;5:16. 11. Gupta RS et al. Pediatrics. 2018;142(6):e20181235. 12. Warren C et al. J Allergy Clin Immunol. 2021;147(6):2263-2270.e5. 13. Dahlsgaard KK et al. Ann Allergy Asthma Immunol. 2025;134(5):525-532. 14. Schauberger EM, Singh AM. J Food Allergy. 2020;2(1):59-63. 15. Lieberman JA et al. Allergy. 2021;76(5):1367-1384. 16. Nocerino R et al. Children (Basel). 2024;11(12):1485. 17. Data on File. DBV Technologies. 18. Clinicaltrials.gov. Accessed November 6, 2025. https://clinicaltrials.gov/study/NCT07003919 19. News release. DBV Technologies. December 16, 2025. 20. Clinicaltrials.gov. Accessed November 6, 2025. https://clinicaltrials.gov/study/NCT05741476 21. Greenhawt M et al. N Engl J Med. 2023;388(19):1755-1766. 22. Greenhawt M, Wang J, Du Toit G, et al. Poster Presented at: Eastern Food Allergy & Comorbidity Conference 2025: Palm Beach, FL. 23. News release. DBV Technologies. February 2, 2026.

© 2026 DBV Technologies. VIASKIN® is a registered trademark of DBV Technologies. All rights reserved. 2026-MLR-088 https://dbv-technologies.com